The immune system deploys a multitude of innate and adaptive mechanisms not only to
ward off pathogens but also to prevent malignant transformation (“immune surveillance”) …

Rituximab, a human/mouse chimeric anti-CD20 antibody, has become part of standard
therapy for patients with CD20-expressing B-cell lymphoma, and is currently under …

Background In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory …

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin
lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up …

Few patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) achieve
prolonged disease-free survival. Blinatumomab, a bispecific T-cell engaging antibody …

Purpose This study evaluates the safety and efficacy of plerixafor (AMD3100), a CXCR4
antagonist, in mobilizing hematopoietic stem cells for autologous stem-cell transplantation in …

We previously reported that remission duration< 1 year, extranodal disease, and B
symptoms before salvage chemotherapy (SLT) can stratify relapsed or refractory Hodgkin …

Salvage of patients with relapsed and refractory Hodgkin disease (HD) with high-dose
chemoradiotherapy (HDT) and autologous stem cell transplantation (ASCT) results in event …

Purpose In studies of diffuse large B-cell lymphoma, positron emission tomography with
[18F] fluorodeoxyglucose (FDG-PET) performed after two to four cycles of chemotherapy has …

Patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) who
achieve complete response (CR) before autologous stem cell transplantation (ASCT) …